TREM2 Antibodies Modulate Immune Response Without Ligand Competition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-TREM2 antibodies are limited in their therapeutic utility as they either block interaction between TREM2 and its natural ligands, mimicking disease-causing loss of function phenotypes, or require clustering to induce agonistic activity, posing safety and efficacy risks, and there is a need for antibodies that specifically bind TREM2 on the cell surface to modulate its activities safely and effectively for treating various diseases.
Innovation Solution
Development of monoclonal, chimeric, or humanized antibodies that specifically bind to TREM2, including agonist and antagonist types, which can activate or inhibit TREM2 activities without competing with ligands, ensuring safe and effective modulation of TREM2 functions on the cell surface to treat conditions such as dementia, cancer, and inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TREM2 antibodies block interaction between TREM2 and its natural ligands, then TREM2 activity is inhibited, but this mimics disease-causing loss of function phenotypes and increases disease risks
Solution Approach 1:
The antibody is designed to bind specifically to TREM2 on the cell surface with localized agonist activity, creating a spatially differentiated effect where TREM2 is activated at the cell surface (where needed for therapeutic effect) while avoiding systemic blockade of ligand binding. This local quality approach allows selective modulation without mimicking complete loss-of-function mutations.
Solution Approach 2:
The invention changes the functional parameter of TREM2 modulation from antagonism (blocking ligand binding) to agonism (activating TREM2 signaling). By altering the mode of action from inhibition to activation, the antibody achieves therapeutic benefit without causing the harmful loss-of-function effects associated with blocking TREM2-ligand interactions.
2Reliability
If anti-TREM2 antibodies require clustering to induce agonistic activity, then TREM2 can be activated, but this poses safety and efficacy risks
Solution Approach 1:
The invention extracts the clustering requirement from the mechanism of TREM2 activation. The antibody is engineered to induce agonistic activity through mechanisms that do not depend on antibody clustering, such as direct monovalent binding or alternative signaling initiation. This removes the safety and efficacy risks associated with clustering requirements while maintaining the ability to activate TREM2.
Solution Approach 2:
The antibody serves as an intermediary that activates TREM2 through a simplified mechanism bypassing the need for clustering. By acting as a direct agonist that can initiate signaling without requiring multiple antibody molecules to cluster, the invention eliminates the uncertainties and risks associated with clustering-dependent activation while maintaining therapeutic efficacy.
3Measurement precision
If anti-TREM2 antibodies are designed to bind TREM2 on cell surface, then specific modulation is achieved, but competing with ligands for binding sites may block natural TREM2 function
Solution Approach 1:
Instead of blocking TREM2 function by competing with ligands for binding sites (the conventional antagonistic approach), the invention inverts the approach by designing an antibody that binds TREM2 and activates it agonistically. This inverted mechanism achieves specific binding while promoting rather than blocking natural TREM2 function, eliminating the harmful blockade effect.
Data Source
AI summary
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.